Cargando…

Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation: A Pilot Randomized Trial

Detalles Bibliográficos
Autores principales:	Kim, Jong S., Lee, Kyung-Bok, Chang, Dae-Il, Cha, Jae-Kwan, Lee, Ji Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Stroke Society 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250868/ https://www.ncbi.nlm.nih.gov/pubmed/37282378 http://dx.doi.org/10.5853/jos.2023.00325

Ejemplares similares

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
por: Baldus, Stephan, et al.
Publicado: (2023)

Transesophageal Echocardiography in Ischemic Stroke With Atrial Fibrillation
por: Tanaka, Kanta, et al.
Publicado: (2021)

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
por: Diaz, Alejandro Bimbo, et al.
Publicado: (2023)

Characteristics of Pulmonary Vein Enlargement in Non-Valvular Atrial Fibrillation Patients with Stroke
por: Lee, Jung Myung, et al.
Publicado: (2014)

Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study)
por: Frisullo, Giovanni, et al.
Publicado: (2020)

Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
por: Ono, Ryohei, et al.
Publicado: (2022)

A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation
por: Shang, Luxiang, et al.
Publicado: (2021)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation
por: Kim, Chi Kyung, et al.
Publicado: (2013)

Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease
por: Ahmad, Saad, et al.
Publicado: (2016)

Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea
por: Bae, Hee-Joon, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)

Role of hyperhomocysteine, thyroid dysfunction and their interaction in ischemic stroke patients with non-valvular atrial fibrillation
por: Wang, Lili, et al.
Publicado: (2020)

Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation have a Risk for Aortogenic Embolizations
por: Kojima, Keisuke, et al.
Publicado: (2021)

Complex Aortic Arch Atherosclerosis in Acute Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation
por: Suzuki, Masayuki, et al.
Publicado: (2021)

Protocol for LASER: A Randomized Evaluation and an Associated Registry of Early Anticoagulation With Edoxaban After Ischemic Stroke in Patients With Atrial Fibrillation
por: Alrohimi, Anas, et al.
Publicado: (2021)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
por: Acharya, Tushar, et al.
Publicado: (2015)

Response to “Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation have a Risk for Aortogenic Embolizations”
por: Suzuki, Masayuki, et al.
Publicado: (2021)

Ischemic stroke risk factors not included in the CHADS-VASC score in patients with non-valvular atrial fibrillation
por: Le Goff, Laurine, et al.
Publicado: (2023)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
por: Lin, Shin-Yi, et al.
Publicado: (2021)

Atrial Fibrillation Related and Unrelated Stroke Recurrence Among Ischemic Stroke Patients With Atrial Fibrillation
por: Kim, Bum Joon, et al.
Publicado: (2021)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
por: Hwang, Ki Won, et al.
Publicado: (2023)

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing
por: Suwa, Michihiro, et al.
Publicado: (2023)

Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
por: Hagii, Joji, et al.
Publicado: (2021)

Effect of advanced age on plasma homocysteine levels and its association with ischemic stroke in non-valvular atrial fibrillation
por: Yao, Yan, et al.
Publicado: (2017)

Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range
por: Wańkowicz, Paweł, et al.
Publicado: (2018)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
por: Kirchhof, Paulus, et al.
Publicado: (2022)

Impact of age on thromboembolic events in patients with non‐valvular atrial fibrillation
por: Kim, Yun Gi, et al.
Publicado: (2019)

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
por: Fukamachi, Daisuke, et al.
Publicado: (2022)

Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation
por: Kim, Young Dae, et al.
Publicado: (2015)

CHA2DS2-VASc score in acute ischemic stroke with atrial fibrillation: results from the Clinical Research Collaboration for Stroke in Korea
por: Lee, Hak-Loh, et al.
Publicado: (2021)

Comparison of Prolonged Atrial Electromechanical Delays with Different Definitions in the Discrimination of Patients with Non-Valvular Paroxysmal Atrial Fibrillation
por: Lee, Dong Hyun, et al.
Publicado: (2015)

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing
por: Suwa, Michihiro, et al.
Publicado: (2023)

Nonlinear relationship between serum total bilirubin levels and initial ischemic stroke in patients with non-valvular atrial fibrillation
por: Liu, Ying, et al.
Publicado: (2020)

Infarct Volumes of Patients with Acute Ischemic Stroke Receiving Direct Oral Anticoagulants due to Non-Valvular Atrial Fibrillation
por: Yavasoglu, Nese G., et al.
Publicado: (2021)

Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation
por: Alberts, Mark, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g51od5fnbr5qds1ocmt6nsi4bn